satranidazole profile

Satranidazole is a nitroimidazole derivative with potent antiprotozoal activity against various parasitic infections, including giardiasis, trichomoniasis, and amebiasis. Its synthesis involves a multi-step process starting with 2-nitroimidazole. Satranidazole is known for its high efficacy and good tolerability in clinical trials. Its mechanism of action involves the reduction of the nitro group within the parasite, generating reactive intermediates that disrupt DNA synthesis and lead to parasite death. Research on satranidazole focuses on its potential for treating various parasitic infections, understanding its pharmacokinetic properties, and exploring its potential use in combination therapies. The compound is studied due to the increasing prevalence of parasitic infections, the emergence of drug resistance, and the need for new and effective treatment options.'

satranidazole: anti-bacterial used to treat periodontitis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	41841
CHEMBL ID	2105542
SCHEMBL ID	1682863
MeSH ID	M0106194

Synonym
c-10213-go
satranidazole
go-10213
go 10213
satranidazole [inn]
brn 0848345
2-imidazolidinone, 1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)-
satranidazolum [latin]
satranidazol [spanish]
c 10213 go
1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)-2-imidazolidinone
1-(1-methyl-5-nitroimidazol-2-yl)-3-(methylsulfonyl)-2-imidazolidinone
1-methylsulfonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone
1-(1-methyl-5-nitroimidazol-2-yl)-3-methylsulfonylimidazolidin-2-one
56302-13-7
CHEMBL2105542
satranidazol
5-25-09-00447 (beilstein handbook reference)
satranidazolum
unii-4n7g8a6439
4n7g8a6439 ,
satranidazole [mart.]
satranidazole [who-dd]
SCHEMBL1682863
DTXSID60204840
1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)imidazolidin-2-one ,
3-(1-methyl-5-nitroimidazol-2-yl)-1-methylsulfonyl-imidazolidin-2-one
Q27260233
A924024
AKOS040746324

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
"Administration of 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazole-yl)-2-imidazolidinone (Go 10213) at a dose of 5000 mg/kg to rat, mouse, guinea pig and rabbit and 3000 mg/kg to dog did not induce any toxic symptoms or mortality."	( Pre-clinical toxicity studies on the new nitroimidazole 1-methylsulphonyl-3-(1-methyl-5-nitroimidazole-2-yl)-2- imidazolidinone. Gangoli, SD; Marathe, MR; Nair, TB; Rao, RR, 1985)	0.27
" The incidence of adverse effects was significantly lower in the group given satranidazole (P < ."	( Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. Kar, P; Madan, K; Muzaffar, J; Sharma, MP, 2006)	0.77

Pharmacokinetics

The pharmacokinetic properties of metronidazole and satranidazoles were studied in the golden hamster (Mesocricetus auratus) The present investigation deals with formulation of stable nanocrystals of poorly soluble satranodazole.

Excerpt	Reference	Relevance
"The pharmacokinetic properties of metronidazole and satranidazole were studied in the golden hamster (Mesocricetus auratus), at a dose of 80 mg/kg po."	( Comparative pharmacokinetics and amoebicidal activity of metronidazole and satranidazole in the golden hamster, Mesocricetus auratus. Bhopale, KK; Kaul, CL; Masani, KB; Pargal, A; Pradhan, KS; Rao, C, 1993)	0.77
" The present investigation deals with formulation of stable nanocrystals of poorly soluble satranidazole (SAT) for improving dissolution rate and pharmacokinetic profiling."	( Mechanistic investigation of biopharmaceutic and pharmacokinetic characteristics of surface engineering of satranidazole nanocrystals. Dhat, S; Kokare, C; Pund, S; Sharma, P; Shrivastava, B, 2016)	0.87

Bioavailability

Excerpt	Reference	Relevance
"The designing of surface engineered nanocrystals for improved stability and bioavailability is a multivariate process depending on several critical formulation and process variables."	( Mechanistic investigation of biopharmaceutic and pharmacokinetic characteristics of surface engineering of satranidazole nanocrystals. Dhat, S; Kokare, C; Pund, S; Sharma, P; Shrivastava, B, 2016)	0.65

Dosage Studied

Excerpt	Relevance	Reference
" The results show that at equivalent dosage schedules with repeated high dosages, Go-10213 is devoid of adverse central and peripheral neural effects in monkeys; cats and dogs, whereas unequivocal evidence of metronidazole neurotoxicity was obtained in all the three species."	( Pharmacological profile of 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (Go-10213), a new antiprotozoal agent, in comparison with metronidazole. Acharya, TK; David, J; Grewal, RS; Kaul, CL; Nargunde, HS; Ringe, SY; Wagle, GP, 1985)	0.27
" Both metronidazole and satranidazole were administered as single graded doses po, and their dose-response profiles were characterized."	( Comparative pharmacokinetics and amoebicidal activity of metronidazole and satranidazole in the golden hamster, Mesocricetus auratus. Bhopale, KK; Kaul, CL; Masani, KB; Pargal, A; Pradhan, KS; Rao, C, 1993)	0.82
" SAT has low polar surface area, high dose and dosing frequency."	( Mechanistic investigation of biopharmaceutic and pharmacokinetic characteristics of surface engineering of satranidazole nanocrystals. Dhat, S; Kokare, C; Pund, S; Sharma, P; Shrivastava, B, 2016)	0.65

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	13 (56.52)	18.7374
1990's	3 (13.04)	18.2507
2000's	3 (13.04)	29.6817
2010's	4 (17.39)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (17.39%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (82.61%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	1.97	1	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
mescaline Mescaline: Hallucinogenic alkaloid isolated from the flowering heads (peyote) of Lophophora (formerly Anhalonium) williamsii, a Mexican cactus used in Indian religious rites and as an experimental psychotomimetic. Among its cellular effects are agonist actions at some types of serotonin receptors. It has no accepted therapeutic uses although it is legal for religious use by members of the Native American Church.. mescaline : A phenethylamine alkaloid that is phenethylamine substituted at positions 3, 4 and 5 by methoxy groups.	1.96	1	0	methoxybenzenes; phenethylamine alkaloid; primary amino compound	hallucinogen
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	4.96	9	1	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	1.97	1	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	1.96	1	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
niridazole Niridazole: An antischistosomal agent that has become obsolete.	1.96	1	0	1,3-thiazoles; C-nitro compound
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	7.03	23	4	C-nitro compound; imidazoles	antitubercular agent
melarsonic acid melarsonic acid: RN given refers to parent cpd	1.97	1	0
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	1.96	1	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
fexinidazole fexinidazole: structure given in first source	1.97	1	0
secnidazole [no description available]	1.96	1	0	C-nitro compound; imidazoles; secondary alcohol	epitope
mk 436 MK 436: structure	1.97	1	0
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	1.97	1	0	metalloid atom; pnictogen	micronutrient
nifurtimox Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.	1.97	1	0	nitrofuran antibiotic
chitosan [no description available]	2.03	1	0

Condition	Relationship Strength	Studies	Trials
Attachment Loss, Periodontal [description not available]	4.45	2	2
Adult Periodontitis [description not available]	4.45	2	2
Dental Plaque A film that attaches to teeth, often causing DENTAL CARIES and GINGIVITIS. It is composed of MUCINS, secreted from salivary glands, and microorganisms.	3.47	1	1
Pocket, Periodontal [description not available]	4.45	2	2
Periodontal Pocket An abnormal extension of a gingival sulcus accompanied by the apical migration of the epithelial attachment and bone resorption.	4.45	2	2
Diabetes Mellitus, Adult-Onset [description not available]	3.5	1	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	3.5	1	1
Pericementitis [description not available]	2.05	1	0
Gingivitis Inflammation of gum tissue (GINGIVA) without loss of connective tissue.	2.05	1	0
Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)	7.05	1	0
Taste Disorder, Anterior Tongue [description not available]	3.41	1	1
Abscess, Amebic, Hepatic [description not available]	4.06	3	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	3.41	1	1
Amebiasis, Intestinal [description not available]	2.65	3	0
Cecal Diseases Pathological developments in the CECUM.	2.36	2	0
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	1.96	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.96	1	0
Infections, Trichomonas [description not available]	1.96	1	0
Trichomonas Infections Infections in birds and mammals produced by various species of Trichomonas.	1.96	1	0
Bacterial Disease [description not available]	3.76	2	1
Bacterial Infections Infections by bacteria, general or unspecified.	3.76	2	1
Brain Disorders [description not available]	1.97	1	0
African Sleeping Sickness [description not available]	1.97	1	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	1.97	1	0
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	1.97	1	0
Blood Poisoning [description not available]	3.35	1	1
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	3.35	1	1
Nervous System Disorders [description not available]	1.96	1	0
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	1.96	1	0

satranidazole

Description

Cross-References

Synonyms (30)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Research

Studies (23)

Market Indicators

Research Demand Index: 53.95

Study Types

satranidazole

Description

Cross-References

Synonyms (30)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Research

Studies (23)

Market Indicators

Research Demand Index: 53.95

Study Types

Related Drugs (15)

Related Conditions (29)